

Quality-Data Code Submission Error Report 2nd Quarter 2012 Physician Quality Reporting System

Report Date: 10/26/2012

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

QDC Submission Attempts:

- Total QDCs Reported - The number of instances where a TIN/NPI submitted a QDC for that measure.
- Total Valid QDCs Reported on Eligible Cases - The number of instances where a TIN/NPI submitted a valid QDC for that measure.
- % Valid – Percentage of Total Valid QDCs Reported divided by Total QDCs Reported on Eligible Cases.
- Total QDCs Reported on Eligible Cases – Number of valid or invalid QDCs reported on eligible cases meeting the measure's denominator requirements.

Denominator Mismatch:

- Measure Reported with Incorrect Age and/or Gender - The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.
- Incorrect Diagnosis and/or HCPCS - The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
- Measure Reported on an Instance with a Missing CPT Code - The number of occurrences of QDC reporting when there are no CPT codes for billable services on the claim associated with the denominator requirements for the measure.

How to Read the Quality-Data Code Submission Error Report by Measure:

Using Measure #1-Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus as an example, we find the following information as we read across each column:

402,470 QDC submissions were received for this measure, 327,387 of which were considered valid. Therefore, the Valid Submission Rate is 81.34%. There were a total of 327,763 QDCs reported on eligible cases. The rest of the columns explain reasons for invalid submissions for measure #1. We see that 57,396 (14.26%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 71,025 (17.653%) submissions were for patient encounters and/or diagnoses that are not listed in the denominator; 1,598 (0.40%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, TIN/NPI.

Analysis Findings Include:
Quality-Data Code Submission Error Report by Individual Measure (Claims)

1. The top 5 measures with the highest percentage of valid QDC codes submitted were:
 - #179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (98.30%),
 - #177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity (97.81%),
 - #147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy (97.73%),
 - #108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (97.31%), and
 - #225 Radiology: Reminder System for Mammograms (96.72%).

2. The top 5 measures with the lowest percentage of valid QDC codes submitted (with at least 1 eligible instance) were:
 - #66 Appropriate Testing for Children with Pharyngitis (0.00%) -- (only 1 eligible instance reported),
 - #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (0.54%),
 - #122 Adult Kidney Disease: Blood Pressure Management (4.22%),
 - #231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (4.56%), and
 - #255 Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure (8.00%).

3. The 5 measures with the highest rate of HCPCS/diagnosis errors were:
 - #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (100.00%),
 - #123 Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL (99.63%),
 - #188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (99.02%),
 - #66 Appropriate Testing for Children with Pharyngitis (98.52%), and
 - #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (95.46%).

4. The 5 measures with the highest rate of patient age/gender errors were:
 - #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (100.00%),
 - #66 Appropriate Testing for Children with Pharyngitis (99.26%),
 - # 231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (89.65%),
 - #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (88.41%), and
 - #64 Asthma: Assessment of Asthma Control (76.43%).

Physician Quality Reporting - Quality Data Code Submission Error Report by Individual Measure (Claims)

Report Includes Claims Data for Services Provided from January 1, 2012 through June 29, 2012 and Processed by June 29, 2012

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	402,470	327,387	81.34%	327,763	57,396	14.26%	71,025	17.65%	1,598	0.40%
#2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	362,129	292,657	80.82%	293,102	50,646	13.99%	65,866	18.19%	1,402	0.39%
#3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	439,629	307,821	70.02%	320,009	74,106	16.86%	114,781	26.11%	1,744	0.40%
#6 Coronary Artery Disease (CAD): Antiplatelet Therapy	305,396	285,678	93.54%	285,678	0	0.00%	19,087	6.25%	587	0.19%
#9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	11,124	8,717	78.36%	8,717	0	0.00%	2,252	20.24%	120	1.08%
#10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	296,614	261,347	88.11%	270,733	2	0.00%	24,329	8.20%	1,223	0.41%
#12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	723,003	621,996	86.03%	622,424	0	0.00%	98,738	13.66%	1,419	0.20%
#14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	726,527	698,216	96.10%	698,424	739	0.10%	26,643	3.67%	1,345	0.19%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	236,433	193,104	81.67%	193,123	0	0.00%	42,655	18.04%	444	0.19%
#19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	176,668	101,370	57.38%	125,398	0	0.00%	50,754	28.73%	322	0.18%
#20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	80,826	56,256	69.60%	56,256	0	0.00%	23,639	29.25%	931	1.15%
#21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	91,579	66,956	73.11%	66,957	4	0.00%	23,825	26.02%	797	0.87%
#22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	90,417	50,139	55.45%	61,619	4	0.00%	27,881	30.84%	917	1.01%
#23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	83,282	59,979	72.02%	59,980	5	0.01%	22,611	27.15%	691	0.83%
#24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	3,987	2,899	72.71%	2,900	36	0.90%	1,053	26.41%	15	0.38%
#28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	38,031	35,841	94.24%	35,843	0	0.00%	1,978	5.20%	136	0.36%
#30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	2,094,326	1,666,717	79.58%	1,674,580	104	0.00%	409,574	19.56%	10,172	0.49%
#31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	16,088	13,626	84.70%	13,626	0	0.00%	2,396	14.89%	49	0.30%

^a The number of instances where a TIN/NPI submitted a QDC for that measure.

^b The number of instances where a TIN/NPI submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: CMMI demonstration participants are excluded from this report.

Note: Group Practice Reporting participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#32 Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	10,721	9,132	85.18%	9,132	0	0.00%	1,418	13.23%	128	1.19%
#35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	11,456	8,227	71.81%	8,598	0	0.00%	2,791	24.36%	51	0.45%
#36 Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	8,594	7,258	84.45%	7,258	0	0.00%	1,229	14.30%	71	0.83%
#39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	293,362	269,595	91.90%	269,595	13,855	4.72%	21,773	7.42%	1,994	0.68%
#40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	13,673	6,738	49.28%	6,738	143	1.05%	6,643	48.58%	74	0.54%
#41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	34,550	27,547	79.73%	27,547	281	0.81%	6,762	19.57%	196	0.57%
#43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	11,563	7,360	63.65%	7,361	0	0.00%	4,099	35.45%	103	0.89%
#44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	8,359	5,101	61.02%	5,101	0	0.00%	3,173	37.96%	85	1.02%
#45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	13,667	2,388	17.47%	11,544	0	0.00%	1,996	14.60%	127	0.93%
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	26,086	3,757	14.40%	9,879	1,051	4.03%	2,503	9.60%	902	3.46%
#47 Advance Care Plan	666,789	613,231	91.97%	614,840	29,937	4.49%	48,809	7.32%	3,140	0.47%
#48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	189,519	167,810	88.55%	167,814	13,308	7.02%	20,545	10.84%	1,160	0.61%
#49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	43,493	32,716	75.22%	32,746	2,173	5.00%	10,577	24.32%	73	0.17%
#50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	41,590	31,387	75.47%	31,417	2,125	5.11%	10,010	24.07%	68	0.16%
#51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	78,227	70,342	89.92%	70,342	0	0.00%	7,687	9.83%	174	0.22%
#52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	67,080	47,321	70.54%	62,350	0	0.00%	4,430	6.60%	265	0.40%
#53 Asthma: Pharmacologic Therapy for Persistent Asthma	6,705	916	13.66%	1,667	4,815	71.81%	4,813	71.78%	12	0.18%
#54 Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	644,727	559,324	86.75%	559,328	8,824	1.37%	82,993	12.87%	1,953	0.30%
#55 Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	110,785	93,868	84.73%	93,868	6,255	5.65%	16,238	14.66%	501	0.45%
#56 Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	280,899	251,569	89.56%	251,572	3	0.00%	28,073	9.99%	808	0.29%
#57 Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	281,068	265,558	94.48%	265,558	3	0.00%	14,269	5.08%	867	0.31%
#58 Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	255,344	244,065	95.58%	244,078	3	0.00%	10,264	4.02%	750	0.29%
#59 Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	182,243	174,797	95.91%	174,797	3	0.00%	6,629	3.64%	617	0.34%

^a The number of instances where a TIN/NPI submitted a QDC for that measure.

^b The number of instances where a TIN/NPI submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: CMMI demonstration participants are excluded from this report.

Note: Group Practice Reporting participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#64 Asthma: Assessment of Asthma Control	2,431	438	18.02%	527	1,858	76.43%	1,871	76.96%	1	0.04%
#65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	46	0	0.00%	0	46	100.00%	46	100.00%	0	0.00%
#66 Appropriate Testing for Children with Pharyngitis	135	0	0.00%	1	134	99.26%	133	98.52%	0	0.00%
#67 Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	9,439	8,910	94.40%	8,910	0	0.00%	490	5.19%	38	0.40%
#68 Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	5,366	4,707	87.72%	5,182	0	0.00%	172	3.21%	10	0.19%
#69 Hematology: Multiple Myeloma: Treatment with Bisphosphonates	7,417	7,003	94.42%	7,004	0	0.00%	395	5.33%	17	0.23%
#70 Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	9,769	9,332	95.53%	9,332	0	0.00%	416	4.26%	18	0.18%
#71 Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	47,745	38,186	79.98%	44,639	202	0.42%	2,885	6.04%	202	0.42%
#72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	11,390	9,942	87.29%	10,544	0	0.00%	826	7.25%	17	0.15%
#76 Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	147,489	127,706	86.59%	127,708	0	0.00%	18,405	12.48%	1,376	0.93%
#84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	2,258	1,861	82.42%	2,035	0	0.00%	217	9.61%	4	0.18%
#85 Hepatitis C: HCV Genotype Testing Prior to Treatment	2,136	1,824	85.39%	2,011	0	0.00%	122	5.71%	2	0.09%
#86 Hepatitis C: Antiviral Treatment Prescribed	1,306	1,202	92.04%	1,202	0	0.00%	101	7.73%	1	0.08%
#87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	1,167	994	85.18%	1,049	0	0.00%	116	9.94%	1	0.09%
#89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	2,320	1,802	77.67%	1,803	0	0.00%	508	21.90%	7	0.30%
#90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	314	156	49.68%	214	0	0.00%	93	29.62%	1	0.32%
#91 Acute Otitis Externa (AOE): Topical Therapy	3,860	3,568	92.44%	3,568	0	0.00%	277	7.18%	15	0.39%
#92 Acute Otitis Externa (AOE): Pain Assessment	4,643	3,727	80.27%	3,728	0	0.00%	903	19.45%	7	0.15%
#93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	2,775	2,514	90.59%	2,517	0	0.00%	254	9.15%	4	0.14%
#99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	19,853	15,342	77.28%	15,344	0	0.00%	4,340	21.86%	103	0.52%
#100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	7,766	6,971	89.76%	6,971	0	0.00%	698	8.99%	80	1.03%
#102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	4,485	2,246	50.08%	2,335	0	0.00%	2,096	46.73%	45	1.00%

^a The number of instances where a TIN/NPI submitted a QDC for that measure.

^b The number of instances where a TIN/NPI submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: CMMI demonstration participants are excluded from this report.

Note: Group Practice Reporting participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	2,484	1,993	80.23%	2,057	0	0.00%	393	15.82%	29	1.17%
#105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	3,076	2,752	89.47%	2,836	0	0.00%	205	6.66%	24	0.78%
#106 Major Depressive Disorder (MDD): Diagnostic Evaluation	7,953	5,101	64.14%	5,101	0	0.00%	2,801	35.22%	35	0.44%
#107 Major Depressive Disorder (MDD): Suicide Risk Assessment	21,735	13,320	61.28%	13,321	0	0.00%	8,302	38.20%	81	0.37%
#108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	26,590	25,875	97.31%	25,892	0	0.00%	650	2.44%	45	0.17%
#109 Osteoarthritis (OA): Function and Pain Assessment	63,920	50,160	78.47%	50,182	3	0.00%	12,822	20.06%	589	0.92%
#110 Preventive Care and Screening: Influenza Immunization	696,371	486,358	69.84%	486,358	0	0.00%	203,833	29.27%	0	0.00%
#111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	954,670	897,253	93.99%	897,679	26,962	2.82%	53,403	5.59%	3,588	0.38%
#112 Preventive Care and Screening: Screening Mammography	214,029	151,817	70.93%	151,841	54,832	25.62%	58,438	27.30%	3,750	1.75%
#113 Preventive Care and Screening: Colorectal Cancer Screening	547,787	454,874	83.04%	454,990	73,782	13.47%	88,506	16.16%	4,291	0.78%
#116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	728	312	42.86%	312	355	48.76%	383	52.61%	11	1.51%
#117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	512,682	331,615	64.68%	332,429	164,973	32.18%	173,518	33.85%	1,015	0.20%
#119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	88,285	73,221	82.94%	73,227	12,012	13.61%	13,671	15.49%	438	0.50%
#121 Adult Kidney Disease: Laboratory Testing (Lipid Profile)	19,541	18,253	93.41%	18,253	0	0.00%	1,189	6.08%	91	0.47%
#122 Adult Kidney Disease: Blood Pressure Management	92,533	3,904	4.22%	4,496	0	0.00%	69,879	75.52%	348	0.38%
#123 Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	5,457	0	0.00%	0	0	0.00%	5,437	99.63%	11	0.20%
#124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	9,092,321	8,460,186	93.05%	8,460,186	0	0.00%	577,983	6.36%	54,152	0.60%
#126 Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	140,449	126,246	89.89%	126,246	0	0.00%	13,342	9.50%	720	0.51%
#127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	108,799	101,805	93.57%	101,805	0	0.00%	6,353	5.84%	571	0.52%
#128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	1,009,616	963,253	95.41%	963,253	1	0.00%	38,942	3.86%	7,421	0.74%
#130 Documentation of Current Medications in the Medical Record	5,722,355	5,432,496	94.93%	5,432,496	32	0.00%	256,106	4.48%	33,753	0.59%
#131 Pain Assessment and Follow-Up	344,880	308,609	89.48%	308,609	2	0.00%	33,146	9.61%	3,125	0.91%
#134 Screening for Clinical Depression and Follow-Up Plan	23,804	22,933	96.34%	22,933	0	0.00%	749	3.15%	122	0.51%
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	505,487	484,419	95.83%	486,157	529	0.10%	18,453	3.65%	775	0.15%
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	201,627	175,623	87.10%	186,650	0	0.00%	14,457	7.17%	453	0.22%

^a The number of instances where a TIN/NPI submitted a QDC for that measure.

^b The number of instances where a TIN/NPI submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: CMMI demonstration participants are excluded from this report.

Note: Group Practice Reporting participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	72,647	51,261	70.56%	51,286	0	0.00%	20,456	28.16%	490	0.67%
#145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	490,625	453,446	92.42%	453,547	0	0.00%	33,285	6.78%	3,793	0.77%
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	1,187,451	1,144,707	96.40%	1,148,795	0	0.00%	35,834	3.02%	2,733	0.23%
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	94,027	91,888	97.73%	91,895	0	0.00%	1,845	1.96%	287	0.31%
#154 Falls: Risk Assessment	293,035	221,545	75.60%	262,277	21,304	7.27%	28,973	9.89%	1,785	0.61%
#155 Falls: Plan of Care	68,336	33,545	49.09%	33,552	0	0.00%	0	0.00%	1,943	2.84%
#156 Oncology: Radiation Dose Limits to Normal Tissues	1,666	1,330	79.83%	1,346	0	0.00%	298	17.89%	20	1.20%
#157 Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	314	216	68.79%	216	0	0.00%	98	31.21%	0	0.00%
#158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	2,258	2,030	89.90%	2,030	0	0.00%	214	9.48%	14	0.62%
#163 Diabetes Mellitus: Foot Exam	135,861	90,206	66.40%	90,208	34,735	25.57%	42,341	31.16%	881	0.65%
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	2,474	2,130	86.10%	2,130	1	0.04%	329	13.30%	14	0.57%
#173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	418,949	404,910	96.65%	404,996	0	0.00%	12,348	2.95%	1,605	0.38%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	11,324	9,782	86.38%	11,048	0	0.00%	253	2.23%	14	0.12%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	11,177	10,932	97.81%	10,934	0	0.00%	220	1.97%	20	0.18%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	18,391	10,816	58.81%	10,817	0	0.00%	7,497	40.76%	27	0.15%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	6,890	6,773	98.30%	6,773	0	0.00%	108	1.57%	8	0.12%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	8,285	7,881	95.12%	8,123	0	0.00%	146	1.76%	15	0.18%
#181 Elder Maltreatment Screen and Follow-Up Plan	1,616	1,438	88.99%	1,438	142	8.79%	157	9.72%	21	1.30%
#182 Functional Outcome Assessment	141,916	130,799	92.17%	130,799	2	0.00%	9,759	6.88%	1,358	0.96%
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	1,478	1,219	82.48%	1,219	0	0.00%	254	17.19%	3	0.20%
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	1,446	1,196	82.71%	1,197	0	0.00%	247	17.08%	2	0.14%
#185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	21,220	18,425	86.83%	18,425	0	0.00%	2,651	12.49%	54	0.25%
#186 Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	3,375	1,253	37.13%	1,253	0	0.00%	2,045	60.59%	5	0.15%
#188 Referral for Otolgic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	1,947	0	0.00%	0	0	0.00%	1,928	99.02%	0	0.00%
#189 Referral for Otolgic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	189	45	23.81%	49	0	0.00%	137	72.49%	1	0.53%

^a The number of instances where a TIN/NPI submitted a QDC for that measure.

^b The number of instances where a TIN/NPI submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: CMMI demonstration participants are excluded from this report.

Note: Group Practice Reporting participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#190 Referral for Otolgic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	2,955	2,436	82.44%	2,483	0	0.00%	457	15.47%	14	0.47%
#193 Perioperative Temperature Management	1,646,739	1,554,487	94.40%	1,587,533	0	0.00%	54,068	3.28%	5,138	0.31%
#194 Oncology: Cancer Stage Documented	58,841	54,697	92.96%	54,800	0	0.00%	3,687	6.27%	322	0.55%
#195 Radiology: Stenosis Measurement in Carotid Imaging Reports	311,518	291,522	93.58%	291,983	0	0.00%	18,180	5.84%	1,355	0.43%
#201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	163,010	127,809	78.41%	136,685	0	0.00%	25,676	15.75%	541	0.33%
#204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	172,486	156,782	90.90%	156,782	0	0.00%	15,031	8.71%	573	0.33%
#225 Radiology: Reminder System for Mammograms	699,371	676,438	96.72%	676,438	758	0.11%	20,990	3.00%	1,873	0.27%
#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	2,674,458	2,584,787	96.65%	2,591,013	15	0.00%	72,292	2.70%	11,153	0.42%
#231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting	3,313	151	4.56%	151	2,970	89.65%	2,909	87.81%	3	0.09%
#232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	17,237	93	0.54%	235	15,240	88.41%	16,454	95.46%	4	0.02%
#235 Hypertension (HTN): Plan of Care	77,934	20,728	26.60%	72,143	0	0.00%	4,902	6.29%	791	1.01%
#241 Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	114,458	76,379	66.73%	100,641	0	0.00%	13,368	11.68%	377	0.33%
#245 Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	531	481	90.58%	481	0	0.00%	49	9.23%	0	0.00%
#246 Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	417	336	80.58%	336	0	0.00%	79	18.94%	0	0.00%
#247 Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	33	29	87.88%	29	0	0.00%	4	12.12%	0	0.00%
#248 Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	769	80	10.40%	80	0	0.00%	684	88.95%	0	0.00%
#249 Barrett's Esophagus	16,994	14,152	83.28%	14,152	0	0.00%	2,678	15.76%	140	0.82%
#250 Radical Prostatectomy Pathology Reporting	3,227	2,970	92.04%	2,970	0	0.00%	214	6.63%	42	1.30%
#251 Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	9,363	7,780	83.09%	7,781	0	0.00%	1,460	15.59%	108	1.15%
#252 Anticoagulation for Acute Pulmonary Embolus Patients	832	794	95.43%	794	0	0.00%	27	3.25%	5	0.60%
#253 Pregnancy Test for Female Abdominal Pain Patients	5,521	5,197	94.13%	5,197	57	1.03%	300	5.43%	21	0.38%
#254 Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	132	21	15.91%	21	2	1.52%	10	7.58%	0	0.00%
#255 Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	25	2	8.00%	2	0	0.00%	5	20.00%	1	4.00%
#261 Referral for Otolgic Evaluation for Patients with Acute or Chronic Dizziness	117	102	87.18%	102	0	0.00%	15	12.82%	0	0.00%
#262 Image Confirmation of Successful Excision of Image-Localized Breast Lesion	126	105	83.33%	105	0	0.00%	20	15.87%	1	0.79%

^a The number of instances where a TIN/NPI submitted a QDC for that measure.

^b The number of instances where a TIN/NPI submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: CMMI demonstration participants are excluded from this report.

Note: Group Practice Reporting participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#263 Preoperative Diagnosis of Breast Cancer	128	96	75.00%	96	0	0.00%	25	19.53%	5	3.91%
#266 Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	2,023	1,880	92.93%	1,880	0	0.00%	139	6.87%	4	0.20%
#267 Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	1,465	1,380	94.20%	1,380	0	0.00%	85	5.80%	0	0.00%
#268 Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	130	97	74.62%	97	33	25.38%	28	21.54%	0	0.00%
#317 Preventive Care and Screening: Screening for High Blood Pressure	274,224	263,737	96.18%	263,737	2	0.00%	8,497	3.10%	1,990	0.73%
Total	39,415,592	35,334,843	89.65%	35,628,675	676,805	1.72%	3,498,892	8.88%	194,972	0.49%

^a The number of instances where a TIN/NPI submitted a QDC for that measure.

^b The number of instances where a TIN/NPI submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: CMMI demonstration participants are excluded from this report.

Note: Group Practice Reporting participants are excluded from this report.